Evommune Shares Plunge After EVO756 Fails to Hit Trial Goals; Company Reprioritizes Atopic Dermatitis Program
Evommune Inc reported that its oral candidate EVO756 did not achieve the primary endpoint or secondary endpoints in a randomized, double-blind, placebo-controlled Phase 2b trial in adults with moderate-to-severe atopic dermatitis, triggering a 27% drop in after-hours trading. The company will not pursue EVO756 for atopic dermatitis and will instead…